Skip to main content
. 2012 Jul;97(7):1042–1047. doi: 10.3324/haematol.2011.046896

Figure 1.

Figure 1.

Mutant Shp2 E76K-expressing cells demonstrate hyperactivation of PI3K and sensitivity to LY294002 treatment. (A) WT Shp2-and Shp2 E76K-transduced cells were differentiated into macrophage progenitors and assayed for PI3K activity at baseline and in response to 10 ng/mL GM-CSF for 60 min. Experiment repeated on 2 independent occasions. (B) Proliferation of WT Shp2- and Shp2 E76K-transduced bone marrow LDMNCs in response to GM-CSF 1 ng/mL in the presence of increasing concentrations of LY294002; representative of 2 independent experiments, n=4–5, *P=0.003 and *P<0.0001 comparing WT Shp2-expressing cells in the absence to the presence of LY294002 5 μM and 15 μM, respectively; **P<0.0001 comparing Shp2 E76K-expressing cells in the absence to the presence of LY294002 5 μM and 15 μM, statistics performed using unpaired, two-tailed Student’s t-test. (C) Proliferation of WT Shp2- and Shp2 E76K-transduced bone marrow LDMNCs in response to increasing GM-CSF concentrations in the presence and absence of 5 μM LY294002, n=3, *P<0.05 and **P=0.06 comparing Shp2 E76K-expressing cells in the presence (purple line) and absence of LY294002 (red line), statistics performed using unpaired, two-tailed student’s t test.